Q4 2023 ReShape Lifesciences Inc Earnings Call TranscriptGuruFocus • about 1 month ago
Related Stocks: NAS:RSLS...
Share to Feed
Completed First Surgeries With Next-Generation Lap-Band 2.0 FLEX 2024 Operating Expenses Expected to Decrease by more than 50% Compared to 2023; Reaffirming Commitment to Profitability Conference...
Patent Significantly Strengthens Intellectual Property PortfolioIRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences (Nasdaq: RSLS), the premier physician-led weight loss and...
ReShape Lifesciences Inc. (NASDAQ:RSLS Get Free Report) was the recipient of a significant decline in short interest in March. As of March 15th, there was short interest totalling 428,700...
Nevro (NYSE:NVRO Get Free Report) and ReShape Lifesciences (NASDAQ:RSLS Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the...
2024 Operating Expenses Expected to Decrease by 55.4% Compared to 2023 Company Reaffirms Commitment to Profitability High Priority Search for Synergistic M&A Partner Continues IRVINE...
FLEX Technology Designed to Enhance the Patient Experience Surgeon Training Underway for the Initial Launch of the Lap-Band 2.0 FLEX IRVINE, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ReShape...
First Time Introduction of Lap-Band 2.0 FLEX to the Next Generation of SurgeonsIRVINE, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences (Nasdaq: RSLS), the premier physician-led...